Journal of Pharmaceutical Investigation Records Strong Citation Growth With 5.5 Impact Factor and Q1 Ranking

The Journal of Pharmaceutical Investigation, a peer-reviewed publication covering pharmaceutical sciences and drug delivery research, has reached a new milestone in its editorial visibility, with abstracting and indexing records confirming its inclusion in Science Citation Index Expanded, widely known as SciSearch, since 2021. The journal now carries a Journal Impact Factor of 5.5 for 2022, placing it in the first quartile of its field with a ranking of 48 out of 278 journals in the Pharmacology and Pharmacy category. For a journal whose name reflects its core mission of documenting how pharmaceutical research translates into investigative practice, the achievement marks an important point in how its content is discovered, cited and used by the global research community.

Abstracting and indexing may sound like a dry administrative exercise, but for working scientists it is the infrastructure that determines whether their work is ever seen. When a journal is indexed in a major citation database, every published article gains a standardized record: a structured abstract, author affiliations, subject headings, bibliographic metadata and, critically, a persistent link that other researchers can follow from a search result to the full text. Without that record, even excellent research risks becoming invisible, buried in a journal that search engines and literature reviews rarely surface. Indexing is therefore the mechanism by which a journal’s content enters the bloodstream of scientific communication.

Science Citation Index Expanded, maintained within the Web of Science ecosystem, is one of the most selective and widely recognized of these databases. Journals admitted to the index undergo evaluation of their editorial rigor, publishing standards, peer-review processes, international authorship and citation behavior. Inclusion since 2021 means that all content published by the Journal of Pharmaceutical Investigation from that point onward is systematically captured, allowing citation links to accumulate year by year. This is a prerequisite for any journal that hopes to receive a Journal Impact Factor, the most discussed single number in scholarly publishing.

The Journal Impact Factor itself is a deceptively simple calculation. In any given year, it counts the citations received in that year by items a journal published in the two preceding years, divided by the number of substantive, citable items, chiefly research articles and reviews, published in those same two years. A 2022 impact factor of 5.5 therefore reflects citations earned during 2022 by material published in 2020 and 2021. That figure indicates that, on average, each citable article from those years was cited more than five times within the measurement window, a level of citation intensity that places the journal firmly among the most influential publications in its discipline.

Just as significant as the raw score is the category ranking: 48th out of 278 journals in Pharmacology and Pharmacy. Citation density varies enormously between fields, so a raw impact factor means little until it is contextualized within a discipline. Quartile placement provides that context. A first-quartile position, corresponding to the top 25 percent of journals in the category, signals to authors, reviewers, librarians and funding bodies that the journal sits within the leading tier of venues for pharmaceutical research. It is this rank, rather than the number alone, that most often determines where researchers choose to submit their best work.

For pharmaceutical scientists, the practical consequences are concrete. A Q1 journal with a 5.5 impact factor becomes a preferred destination for studies on novel drug delivery systems, pharmacokinetics, formulation science, nanotechnology-based therapeutics and clinical investigation of new compounds. Authors gain the assurance that their papers will be read by a broad, international audience and that citations will be tracked and attributed correctly. Readers gain the assurance that the journal’s editorial standards have been vetted by an independent indexing body. Institutions, in turn, use these indicators when evaluating faculty productivity, since indexed, highly ranked publications carry more weight in hiring, promotion and grant assessments.

The timing of the indexing also matters. A journal’s early years in a citation index are typically characterized by incomplete citation trails, because it takes time for the database to record references pointing back to newly indexed content. As the 2021 entry point recedes, successive impact factor cycles will draw on an increasingly complete record of the journal’s output. This dynamic often produces a period of citation growth, as previously published articles continue to accrue citations while the denominator of citable items stabilizes. The 2022 figure of 5.5 should therefore be read not as a static endpoint but as a data point in an ongoing trajectory of the journal’s scientific footprint.

It is worth pausing on why metrics like these attract such intense attention, and also on their limits. The Journal Impact Factor was originally designed as a library-management tool, a way to help librarians decide which journals to subscribe to, not as a measure of the quality of any individual paper. A citation to an article can be positive, negative or merely incidental, and citation counts are influenced by article type, review coverage and field trends. Editors and bibliometricians have long cautioned against grading individual researchers by the impact factor of the journals in which they publish. Nevertheless, at the level of the journal as a whole, the metric remains a fast, transparent and universally understood signal of scholarly influence, and quartile rankings in particular continue to shape real decisions across the research enterprise.

Within pharmaceutical science specifically, the value of strong indexing infrastructure is amplified by the field’s translational character. Research published in these pages informs drug formulation, bioavailability enhancement, controlled-release technology, pharmacoeconomics and regulatory science, and its audience spans academic laboratories, industrial research and development groups, clinical pharmacologists and regulatory reviewers. When a study on a novel nanoparticle carrier or an improved oral delivery platform is properly abstracted and indexed, it can be retrieved by a formulator searching for prior art, by a regulatory scientist drafting a dossier or by a clinician weighing a new therapeutic approach. Each of those retrieval events is a potential citation, and each citation strengthens the record on which the journal’s ranking rests. Indexing, citation and scientific progress form a single feedback loop.

The Journal of Pharmaceutical Investigation’s combined achievement, inclusion in Science Citation Index Expanded since 2021, a 2022 Journal Impact Factor of 5.5 and a Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, therefore represents more than a publishing success. It reflects the cumulative choices of thousands of authors who selected the journal as the home for their work, the reviewers and editors who upheld its scientific standards, and the researchers worldwide whose citations now register in the databases that measure contemporary science. As the journal’s indexed archive matures, its bibliometric record will continue to evolve, and the pharmaceutical research community will be watching how that trajectory develops in the annual release of citation reports to come.

Beyond the headline numbers, the mechanics of how a journal enters and moves through the citation ecosystem deserve closer attention. Science Citation Index Expanded traces its lineage to the Citation Index for Science created in the 1960s, when bibliographers first demonstrated that references embedded in published papers could be aggregated into a searchable network of scholarly influence. That insight, that citations function as explicit acknowledgments of prior intellectual debt, remains the conceptual foundation of modern bibliometrics, and every impact factor calculated today descends from it.

The distinction between being indexed and being measured is also worth clarifying. Journals admitted to Science Citation Index Expanded receive standardized bibliographic records and become part of the citation network, but the Journal Impact Factor itself is released through a separate annual reporting process that evaluates journals after a period of consistent indexing. This staged progression explains why newly indexed journals often need several annual cycles before their metrics stabilize, and why the 2022 assessment of the Journal of Pharmaceutical Investigation represents an early but meaningful reading of its citation performance rather than a mature one.

For authors deciding where to submit, indexing status interacts with other practical considerations. Pharmaceutical research is a fast-moving field in which preprints, conference proceedings and patent literature all compete for attention, so the assurance that a journal’s records are systematically captured and cross-linked carries real weight. Standardized metadata also enables bibliometric tools to disambiguate authors with similar names, connect related datasets and track the diffusion of a finding across disciplines, functions that become increasingly important as pharmaceutical science grows more interdisciplinary, drawing on chemistry, biology, engineering and clinical medicine simultaneously.

The category in which the journal is ranked deserves note as well. Pharmacology and Pharmacy is a broad and crowded classification that encompasses basic pharmacological research, drug design, clinical therapeutics and pharmacy practice, meaning journals compete for citation attention across quite different audiences. Achieving a position within the top quartile of such a heterogeneous category suggests that the journal’s content resonates beyond a narrow specialty, attracting citations from multiple subfields rather than from a single tightly knit community. Cross-disciplinary citation of this kind is often cited by editors as a sign of durable relevance.

Finally, the broader publishing environment shapes how such metrics should be interpreted. Scholarly communication is undergoing sustained change, with open access models, alternative metrics and funder mandates altering how research is disseminated and discovered. Citation-based measures remain the most established currency of journal evaluation, but they increasingly sit alongside downloads, altmetric attention and policy citations in a fuller picture of impact. Within that evolving landscape, a journal that combines rigorous peer review, international reach and strong indexed performance is well positioned to remain a trusted venue as the standards by which science is assessed continue to develop.

Subject of Research: Abstracting and indexing of pharmaceutical research journals and citation metrics

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: abstracting and indexing, Science Citation Index Expanded, SciSearch, Journal Impact Factor, pharmacology, pharmacy, Q1 journal, citation metrics, Web of Science, pharmaceutical investigation, journal ranking, scholarly publishing